Bio-Solutions Corp. (BISU-OTC: BB)

CEOCFO-Members Login

March 26, 2010 Issue

The Most Powerful Name In Corporate News and Information


Bio-Solutions Corp. Is Focused On Two Large Market Areas With Their NutraAnimal™ Organic Feed Supplement For The Poultry Industry And Their GreenEx™ Biological Insecticide To Help Combat Mosquitoes That Carry Deadly Diseases Such As Malaria

Company Profile:

Bio-Solutions Corp. (OTCBB:BISU), markets new and very effective organic products to counter Malaria; our lead product is GREENEX™. Malaria is the forefront of priorities for the World Health Organization. GREENEX™ is an organic insecticide available in solid or liquid form, which neutralizes and eradicates up to 98% of the mosquito larvae, within only a 24 hours period. Today, Malaria is the most dangerous disease transmissible by mosquitoes that we know of. Over 300 million people are infected by this disease and more than one million children under the age of five years die from Malaria each year.


In addition, Bio-Solutions Corp. is a biotechnology company specializing in veterinary care and organic dietary supplements for livestock. Bio-Solutions Corp. prime objective, is to improve the yield in the chain of livestock production based on added value natural products. This approach will accelerate the transfer of innovation towards the market and will allow our company to profit at a faster pace than other companies in the same field.

After 2 years of clinical tests with a highly renowned veterinary expert, Chicken Integrators can now take advantage of a safe and natural supplement for their poultry. NutraAnimal™ is an innovative milled supplement composed of active ingredients of organic marine source. This product represents a natural alternative used as a growth promoter.

Its benefits: Preliminary results have shown that by supplementing the chicken's diet with NutraAnimal™, feed conversion rate was improved by up to 10% with a chicken weight increase of 7%, while decreasing the mortality rate by more than 50%.

Dr. Gilles Chaumillon
President & Chief Executive Officer

Prior joining Bio-Solutions, Dr. Gilles Chaumillon was Senior Director, Project Management for a Canadian medical device company. He has more than 10 years experience in the biotechnology field.

Dr.  Chaumillon had been an executive of BioSyntech Inc., a public company, since the end of 2004. Before, he was General Manager and Business Development Director of a Contract Research Organization. He began his career at Æterna-Zentaris as Director in charge of collaboration network and process development. His experience encompasses product and process development, Manufacturing and also business development, strategic planning and commercialisation.


Dr. Chaumillon is a member of Quebec MBA Association (AMBAQ) and also an active member Quebec Biotech Association (BIOQUEBEC) where he is president of the membership committee.

Dr. Chaumillon holds a PhD degree in marine biology from Laval University of Québec City and a MBA in Biotech Management from UQAM.

Healthcare Biotechnology
Organic Veterinary Products

Bio-Solutions Corp.
14517, Joseph Marc Vermette
Mirabel, QC J7J 1X2 Canada
Phone: 514-601-5677

Interview conducted by: Lynn Fosse, Senior Editor,, Published – March 26, 2010

Mr. Chaumillon, what attracted you to Bio-Solutions?

Mr. Chaumillon: I have been in the biotech sector for more than ten years in several managing positions. Therefore, when I was offered the opportunity to direct a biotech company I was interested. I have been involved in marine biology as my PhD is Marine Biology, and one of the products of Bio Solutions is based on marine resources. Also, the mission of the company:  To develop, integrate and market pioneering organic products that are more effective for animal treatment and care.


CEOCFO: What is the focus of Bio-Solutions today?

Mr. Chaumillon: The focus of Bio-Solutions is mainly in two areas. The first one is a feed supplement for the poultry market that we have developed in our company. The other market is a biological insecticide, and we acquired that license from a company here in Quebec.


CEOCFO: Would you give us more detail about what you are doing in both areas?

Mr. Chaumillon: For the feed supplement, NutraAnimal™, We have already signed , an agreement with a distributor for Canada and we are looking for distributors in these parts of the world. We are currently in negotiation with a distributor in Europe and South America. With our biological insecticide, GreenEx™, we target areas that have a high incidence of Malaria. So we are looking for a contract in Africa. We are currently negotiating with three African countries to have our product and services there.


CEOCFO: How big of a problem is malaria today?

Mr. Chaumillon: Malaria is a huge problem in tropical countries, particularly in Africa. There are more than 300 million people infected by Malaria in Africa and most of them are children. More than one million children under the age of five years die from Malaria each year.


CEOCFO: What is unique about your product GreenEx™?

Mr. Chaumillon: Our GreenEx™ product is a biological insecticide, It targets the larvae of the mosquitoes. It is really important to treat the cause of the disease by killing the problem at the origin, the mosquitoes that carry the malaria. Out product kills up to 98% of the mosquitoes larvae within 48 hours without any impact on the environment.


CEOCFO: What is the competitive landscape like?

Mr. Chaumillon: Usually, chemical insecticides are used to kill mosquitoes ours is biological and organic. GreenEx™ has a longer lifetime in the environment and more stable than similar products.


CEOCFO: What are you doing for the poultry and why is it needed?

Mr. Chaumillon: Today, in the poultry market most of the hormones growing factors are going to be banned. So, chicken producers are moving from the current growth factor systems to biological ones. They are looking for more green products and looking for biological supplements, so NutraAnimal™ is important in that field.


CEOCFO: Development and bringing products to the market is expensive;  what is the financial picture like at Bio-Solutions today?

Mr. Chaumillon: That is why we are looking for distributors. We are a small company and we don’t want to spend so much money on a sales force right now. We will focus on GreenEx™ marketing activities and feed supplements R&D. We are closing our financing to be able to achieve our program.


CEOCFO: What does it take to be successful; is it finding the right people, negotiating the contracts, what is the hard part?

Mr. Chaumillon: The hard part is to find the right partner, one that has access to the clients. That is what we want to target, and always look for a win-win partnership; it is the key.


CEOCFO: Would you tell us about your new website?

Mr. Chaumillon: We have launched a new website that reflects more our focus. We did this because the first website was not very nice and was not explaining exactly what we are targeting. We are also making it more attractive for investors as well.


CEOCFO: Do you have other products in the pipeline; what is the strategy as you go forward?

Mr. Chaumillon: Our focus is on the biological ingredients for livestock feed or health care and other types of biological programs. We are developing partnerships with other companies to develop new products in those areas.


CEOCFO: In closing, address potential investors; why should they pay attention and why does Bio Solutions stand out?

Mr. Chaumillon: First, we are not only in the biotech sector, but in the green biotech sector. In addition, we are in two huge markets with the poultry feed and the biological insecticide. These are large markets, but with our strategy and unique products and turnkey operation services, we are in a good position to achieve our objectives.


Any reproduction or further distribution of this article without the express written consent of is prohibited.


The focus of Bio-Solutions is mainly in two areas. The first one is a feed supplement for the poultry market that we have developed in our company. The other market is a biological insecticide, and we acquired that license from a company here in Quebec. - Dr. Gilles Chaumillon

Featured Industries

Energy | Energy-TechEnergy-Infrastructure | Renewable-EnergyGreen | Environmental-Technology Uranium

Oil & Gas | Jr. Oil & Gas | Natural-Gas | Jr. Oil & Gas-#4 | Shale-Gas | Utica-Shale

Precious-Metals | ResourcesMiningMetals | Gold | Capital Goods | Industrial-Goods | Product-DevelopmentWaste-Management 

Healthcare | Biotechnology | Pharma | Drug-Development | Drug Developent-3 | Vaccine-Development

Medical-Device | Medical-Tech | Medical-Instruments  | Natural-HealthWellness | Animal-Health

Bank |  Financial | Business-Banks |  Community Banks |  Commercial-Bank   | Commercial Banks | Bank-Analyst

Business-Development |  Specialty-Finance |  |   Specialty Finance #2  |  Brokerage Services

Regional-Banks | Regional Bank Analyst Mid-Atlantic | Pacific-Bank | REIT Video-Conference | Telepresence

Clean Technology | Technology | Authentication Telecommunications | Semiconductor | Communications | Retail | Real Estate | Infrastructure does not purchase or make
recommendation on stocks based on the interviews published.